Gene therapy offers hope for rare blindness
NCT ID NCT03374657
First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study tests a new gene therapy called CPK850 for people with a rare form of retinitis pigmentosa caused by mutations in the RLBP1 gene. The therapy is injected under the retina to replace the faulty gene. The main goals are to check safety and see if it helps the eye adjust to darkness better. Only 12 adults with advanced vision loss are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Stockholm, SE-112 82, Sweden
Conditions
Explore the condition pages connected to this study.